<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>maintain</title>

    <!-- bootstrap css -->
    <link rel="stylesheet" href="asset/css/bootstrap.min.css" />
    <!-- owl-carousel  -->
    <link rel="stylesheet" href="asset/css/owl.carousel.min.css" />
    <!-- main CSS -->
    <link rel="stylesheet" href="asset/css/main.css" />
</head>

<body>
    <!-- ========================= -->
    <!-- header section  -->
    <!-- ========================= -->
    <div class="header-top-cnt blue">
        <p>THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY</p>
    </div>
    <header class="header">
        <nav class="navbar navbar-expand-lg navbar-light p-0">
            <div class="collapse navbar-collapse" id="navbarSupportedContent">
                <ul class="navbar-nav align-items-center me-auto">
                    <li class="nav-item">
                        <a href="home.html" class="header-link">
                            <img src="asset/image/Home-icon.png" alt="" />
                            HOME</a>
                    </li>
                    <li class="nav-item active">
                        <a href="patient_experience.html" class="header-link">
                            <img src="asset/image/Patient-icon.png" alt="" />
                            patient experience</a>
                    </li>
                    <li class="nav-item">
                        <a href="about_brintellix.html" class="header-link">
                            <img src="asset/image/AB_ico.png" alt="" />
                            ABOUT BRINTELLIX</a>
                    </li>
                    <li class="nav-item">
                        <a href="#" class="header-link">
                            <img src="asset/image/AE_icon.png" alt="" />
                            report an adverse Event</a>
                    </li>
                    <li class="nav-item">
                        <a href="#" class="header-link">
                            <img src="asset/image/PI_icon.png" alt="" />
                            prescribing information</a>
                    </li>
                </ul>
            </div>
            
            <a class="navbar-brand logo" href="#"><img src="asset/image/logo.png" alt="" /></a>
            <button id="nav-burger">
                <span></span>
                <span></span>
                <span></span>
                <span></span>
            </button>
        </nav>
        <hr class="divider" />
    </header>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel-sec ">
        <div class="li">
            <div class="nav-btn">
                <a href="focus.html" class="arrow-btn"><img src="asset/image/left-arrow.png" alt=""></a>
                <a href="live.html" class="arrow-btn arrow-btn-right"><img src="asset/image/right-arrow.png" alt=""></a>
            </div>
            <figure class="feel-sec-bg">
                <img class="display-sm-none" src="asset/image/feel-sec-bg5.png" alt="" />
                <img class="display-lg-none" src="asset/image/feel-sec-sm-bg5.png" alt="">
            </figure>
            <div class="container">
                <div class="banner-wraper">
                    <p class="major">
                        Brintellix (vortioxetine) is indicated for the treatment of major
                        depressive episodes in adults.¹<br />
                        Prescribing information can be accessed via the tab at the top of
                        this page.
                    </p>
                    <div class="feel-sec-cnt">
                        <h2>I want to MAINTAIN</h2>
                        <figure class="feel-image">
                            <img src="asset/image/feel-sec-img5.png" alt="" />
                        </figure>
                        <h3>
                            Could Brintellix help adult patients diagnosed with MDD like Samantha get closer to achieving recovery and remission?
                        </h3>
                    </div>
                </div>
            </div>
            <ul class="dots-body">
                <li ></li>
                <li></li>
                <li></li>
                <li></li>
                <li class="active"></li>
            </ul>
            <span class="used">Fictional patients used for illustrative purposes.</span>
        </div>
        
    </section>
    <!-- ========================= -->
    <!-- feelings section  -->
    <!-- ========================= -->
    <section class="feelings cmn-banner">
        <figure class="feelings-bg">
            <img class="feelings-bg1" src="asset/image/feelings-bg2.png" alt="" />
            <img class="display-none" src="asset/image/orange-sm-bg.png" alt="">
        </figure>
        <div class="container">
            <div class="row flex-md-column-reverse flex-sm-column-reverse flex-column-reverse flex-lg-row">
                <div class="col-lg-6">
                    <div class="feelings-cnt-left">
                        <div class="feelings-top-cnt">
                            <h4 >After Samantha started taking her SSRIs at the start of this
                                year, she saw an improvement in her symptoms of low mood and hopelessness and finally
                                felt like she was out of the woods.
                            </h4>
                            <p>
                                But after a few months, she stopped taking her treatment due to experiencing
                                side-effects related to sexual functioning.2 Now she’s finding it a struggle to get out
                                of bed again, so she’s worried that she’s experiencing a relapse.
                            </p>
                        </div>
                        <div class="defined-cnt">
                            <h4>Recurrence / relapse in MDD</h4>
                            <p>
                                As many as 1 in 4 individuals who recover from a major depressive episode will have a
                                recurrence within the first year³
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="feelings-cnt-right ">
                        <figure class="round-img">
                            <img src="asset/image/round-img5.png" alt="" />
                        </figure>
                        <h2 class="maintain-h2-padding">
                            Brintellix may help people like Samantha by improving rates of remission (vs. agomelatine)4
                            and reducing the risk of relapse (vs. placebo)⁵
                        </h2>
                        <span class="depressive">MDD, major depressive disorder; SSRI, selective serotonin reuptake
                            inhibitor.</span>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing section  -->
    <!-- ========================= -->
    <section class="design desing2">
        <div class="container2">
            <div class="row desing-row       ">
                <div class="design-left">
                    <h4>
                        Brintellix demonstrates significantly better rates of remission vs. agomelatine in patients with
                        MDD who had suboptimal responses to SSRI/SNRI therapy⁴
                    </h4>
                    <ul class="both">
                        <li>
                            <span class="week">Primary endpoint established noninferiority and showed that Brintellix
                                was superior to agomelatine by 2.2 MADRS points at week 8 (p< 0.01; as measured by
                                    MADRS†)</span>
                        </li>
                        <li>
                            <span class="week">Brintellix was also significantly superior in response rates at Weeks 8
                                and 12 vs. agomelatine (p< 0.01; MADRS responders)</span>
                        </li>
                        <li>
                            <span class="week">The NNT vs. agomelatine for remission at Week 12 was 7 – for every 7
                                patients treated with Brintellix, 1 additional patient achieved remission than with
                                agomelatine</span>
                        </li>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal8">
                        Study design
                    </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="font-size-16">
                            MADRS remission rates†
                        </span>
                        <figure class="char-img1">
                            <img src="asset/image/chart-img13.png" alt="" />
                        </figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Montgomery SA et al. 2014.⁴</span>
                            <span class="adapted">†As measured by MADRS: FAS, MMRM by visit and LOCF (FAS, ANCOVA) at
                                Week 8; ‡p< 0.01; §p< 0.001 vs. agomelatine. Remission was defined as MADRS total score
                                    ≤10 or CGI-S ≤2. At week 8, 40.5% (102/252) of patients treated with Brintellix were
                                    considered MADRS remitters, vs 29.5% (71/241) of patients treated with agomelatine
                                    (LOCF; p< 0.01). </span>
                                    <span class="adapted">Patients included in this study had a mean MADRS baseline
                                        score total score of 28.9 and item score (apparent sadness) of ≥3 at screening
                                        and baseline and were non or partially responsive to a single treatment course
                                        of SSRI or SNRI for ≥6 Weeks. SSRI - citalopram, escitalopram, paroxetine,
                                        sertraline; SNRI - duloxetine or venlafaxine.</span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    ANCOVA, analysis of covariance; FAS, full analysis set; HAM-D, Hamilton Depression Rating Scale;
                    LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Depression Rating Scale; MMRM,
                    mixed model for repeated measures; NNT, number needed to treat; SNRI, serotonin and noradrenaline
                    reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
                </p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing-2 section  -->
    <!-- ========================= -->
    <figure class="desing-sec-sm-img"><img src="asset/image/desing-bg-img.png" alt=""></figure>
    <section class="design position-relative ">
        <div class="container2">
            <div
                class="row desing-row flex-md-column-reverse flex-sm-column-reverse flex-column-reverse flex-lg-row-reverse">
                <div class="design-left">
                    <h4 class="p-0 text-white">
                        Brintellix significantly reduces the risk of relapse vs. placebo in patients with remitted MDD⁵
                    </h4>
                    <ul class="both both-2">
                        <li>
                            <span class="week text-white">In the 48-week, relapse-prevention RESET study, all doses of
                                Brintellix
                                were effective for relapse prevention (5, 10 and 20 mg doses)⁵ </span>
                        </li>
                        <li>
                            <span class="week text-white">Time to relapse was longer and cumulative rates were lower for
                                all
                                Brintellix doses vs. placebo over 28 weeks (p< 0.05 for all):⁵ </span>
                                    <ul class="rounded-bullets">
                                        <li><span class=" font-size-16">Brintellix 5 mg (19.3% vs. placebo 32.5%)</span>
                                        </li>
                                        <li><span class=" font-size-16">Brintellix 10 mg (17.9% vs. placebo
                                                32.5%)</span></li>
                                        <li><span class=" font-size-16">Brintellix 20 mg (17.4% vs. placebo
                                                32.5%)</span></li>
                                    </ul>
                        </li>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal9">
                        Study design
                    </button>
                    <span class="font-size-14-white">MDD, Major Depressive Disorder.</span>
                </div>
                <div class="design-right">

                </div>
            </div>

        </div>
        <span class="used">Fictional patients used for illustrative purposes.</span>
    </section>
    <!-- ========================= -->
    <!-- desing3 section  -->
    <!-- ========================= -->
    
    <section class="design desing2">
        <div class="container2">
            <div
                class="row desing-row flex-row-reverse  flex-lg-row">
                <div class="design-left desing-left2">
                    <h4>
                        Brintellix effectively lessens the burden of depression over the long term³
                    </h4>
                    <p>
                        In a pooled post hoc analysis of the effectiveness, safety and tolerability of Brintellix during
                        five long-term (52-week) open-label extension studies of people with MDD:³
                    </p>
                    <ul class="both">
                        <li>
                            <span class="week">Maintenance therapy with Brintellix was associated with <strong>continued
                                improvement from baseline in depressive symptoms,</strong> assessed by mean MADRS total scores
                                over 52 weeks </span>
                        </li>
                        <li>
                            <span class="week">Anxiety symptoms also improved with long-term maintenance therapy
                                (assessed by HAM-A total score and the global severity impression assessed by CGI-S
                                score)
                            </span>
                        </li>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal10">
                        Study design
                    </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="change">Mean MADRS total scores in randomised controlled trials followed by
                            open-label extension studies (n=1230, LOCF)</span>
                        <figure class="char-img1">
                            <img src="asset/image/chart-img14.png" alt="" />
                        </figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Vieta E et al. 2017.³</span>
                            <span class="adapted pb-2">Mean MADRS total scores from a pooled analysis of patients
                                previously treated with Brintellix 5-20 mg/day in five six-to-eight-week long-term,
                                open-label, randomised controlled trials who continued treatment in an open-label
                                extension study (n=1230) (LOCF). The vertical line represents the start of treatment in
                                the extension phase. The horizontal dashed line indicates the threshold for remission,
                                as defined by MADRS total score ≤10.
                            </span>
                            <span class="adapted">Limitations: Because this was a post hoc analysis, the power to assign
                                statistical significance to differences in outcome measure was limited.
                            </span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    HAM-A, Hamilton Anxiety Rating Scale; LOCF, last observation carried forward; MADRS,
                    Montgomery-Åsberg Depression Rating Scale; MDD, Major Depressive Disorder; MDE, major depressive
                    episode.
                </p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- warnings section  -->
    <!-- ========================= -->
    <section class="warnings">
        <div class="container">
            <div class="warnings-warp">
                <p>
                    For further information about Brintellix, including Tolerability,
                    Special Warnings and Precautions and Contraindications, please visit
                    the About Brintellix Section
                </p>
                <button class="btn-more about-btn">about brintellix</button>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- deserve section  -->
    <!-- ========================= -->
    <section class="deserve">
        <div class="container">
            <div class="deserve-wrap">
                <h3>Explore more in the sections below:</h3>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel">
        <ul class="feel-body">
            <li class="light-orange">
                <h4>
                    I want to <br />
                    FEEL
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img1.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in anhedonia and emotional blunting</p>
                </div>
                <a href="feel.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-2">
                <h4>
                    I want to
                    <br />
                    ACHIEVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img2" src="asset/image/feel-img2.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in work productivity, presenteeism and functioning</p>
                </div>
                <a href="achieve.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-3">
                <h4>
                    I want to <br />
                    MOVE FORWARD
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img3.png" alt="" />
                </figure>
                <div class="function">
                    <p>
                        Brintellix in patients with MDD together with anxiety and a
                        history of trauma
                    </p>
                </div>
                <a href="forward.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-4">
                <h4>
                    I want to <br />
                    FOCUS
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img4.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in cognition</p>
                </div>
                <a href="focus.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-5">
                <h4>
                    I want to <br />
                    MAINTAIN
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img5.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in remission and relapse</p>
                </div>
                <a href="maintain.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-6">
                <h4>
                    I want to <br />
                    LIVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img6.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix and sexual functioning</p>
                </div>

                <a href="live.html" class="btn-more btn-more-2">MORE</a>
            </li>
        </ul>
    </section>
    <!-- ========================= -->
    <!-- reference   section  -->
    <!-- ========================= -->
    <section class="reference">
        <div class="container">
            <div class="reference-wrap">
                <div class="adverse-blk">
                    <span class="events">Adverse events should be reported.
                    </span>
                    <p>Reporting forms and information can be found at <a href="#"
                            class="yellowcard">www.mhra.gov.uk/yellowcard</a> Adverse events should
                        also be reported to Lundbeck Limited, Medical Information, on: <a class="mobile-number" href="tel:01908 638972">01908 638972</a> or Email:
                        <a href="mailto:SafetyLuUnitedKingdom@lundbeck.com" class="yellowcard"> SafetyLuUnitedKingdom@lundbeck.com</a>
                        
                    </p>
                    
                </div>
                <div class="reference-cnt">
                    <span class="ref-head">References</span>
                    <ul class="reference-list">
                        <li>
                            <span>Lundbeck. Brintellix. Summary of Product Characteristics GB and NI.</span>
                        </li>
                        <li>
                            <span>Jacobsen PL et al. J Sex Med 2015;12:2036–2048.
                            </span>
                        </li>
                        <li>
                            <span>Vieta E, et al. European Neuropsychopharmacology. 2017;27(9):877-884.
                            </span>
                        </li>
                        <li>
                            <span>Montgomery SA et al. Hum Psychopharmacol 2014;29:470–482.
                            </span>
                        </li>
                        <li>
                            <span>Thase ME et al. J Affect Disord 2022;303:123–130.
                            </span>
                        </li>
                    </ul>
                    <span class="ref-head">UK-BRIN-1284 | June 2023</span>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- footer   section  -->
    <!-- ========================= -->
    <footer>
        <hr class="footer-divider" />
        <div class="container">
            <div class="row">
                <div class="footer-log d-flex">
                    <a href="#" class="footer-logo"><img src="asset/image/footer-logo.png" alt="" /></a>
                </div>
                <div class="location">
                    <p>
                        Lundbeck Limited <br />
                        Iveco House, Station Road <br />
                        Watford, Hertfordshire <br />
                        WD17 1ET <br />
                        United Kingdom
                    </p>
                    <span class="ref-head">UK-BRIN-1360 | June 2023</span>
                </div>
                <div class="contact">
                    <span class="ref-head">Contact us </span>
                    <a class="mail-link" href="tel:+44 1908 649 966">+44 1908 649 966</a>
                    <a href="mailto:united_kingdom@lundbeck.com" class="mail-link">united_kingdom@lundbeck.com</a>
                </div>
                <div class="footer-link-cnt">
                    <span class="ref-head">Links</span>
                    <ul class="footer-links">
                        <li><a href="#" class="footer-link">Contact us </a></li>
                        <li><a href="#" class="footer-link">Terms of Use</a></li>
                        <li>
                            <a href="#" class="footer-link">Report an Adverse Event</a>
                        </li>
                        <li>
                            <a href="#" class="footer-link">Website Privacy Policy</a>
                        </li>
                        <li><a href="#" class="footer-link">Cookies settings</a></li>
                        <li>
                            <a href="#" class="footer-link">Prescribing information </a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

    <!----------------------- JQUERY ----------------->
    <script src="asset/js/jquery-min.js"></script>

    <!-- BOOTSTRAP JS -->
    <script src="asset/js/bootstrap.bundle.min.js"></script>
    <!----------------------- OWL CAROUSEL ----------------->
    <script src="asset/js/owl.carousel.min.js"></script>
    <!-- script js -->
    <script src="asset/js/script.js"></script>
    <!--study 1  Modal -->
    <div class="modal fade" id="study-modal8" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span>Montgomery SA et al. 2014¹</span>
                    <h3>
                        A randomised, double-blind study in adults with major depressive disorder (MDD) with a
                        suboptimal response to a single course of selective serotonin reuptake inhibitor or
                        serotonin-noradrenaline reuptake inhibitor treatment switched to Brintellix or agomelatine
                        (REVIVE study).
                    </h3>
                    <span class="font-size-16-br"><strong>Study objective:</strong> Compare the efficacy and tolerability of flexible
                        doses of Brintellix vs. agomelatine, after twelve weeks of treatment, in depressive symptoms in
                        patients with MDD who have responded inadequately to antidepressant monotherapy with an SSRI or
                        SNRI.</span>
                        <div class="rotate-sm">
                            <figure><img src="asset/image/rotate.png" alt=""></figure>
                            <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                        </div>
                    <span class="font-size-20-blue pt-3">12-week double-blind treatment period</span>
                    <figure class="vocational">
                        <img src="asset/image/vocational-img7.png" alt="" />
                    </figure>
                    <div class="analysis-cnt">
                        <p>
                           <strong> Primary efficacy endpoint:</strong> Change from baseline in MADRS total score at Week 8 based on the
                            full analysis set using all available data. A non-inferiority followed by a superiority
                            comparison of Brintellix vs. agomelatine was based on estimates from a mixed model for
                            repeated measures.
                        </p>
                        <p>
                            <strong>Secondary efficacy endpoints:</strong> HAM-A total score, CGI-S and CGI-I scores, SDS total score,
                            EQ-5D overall health state score (VAS), WLQ global productivity index, MADRS total score and
                            DFFS total score.
                        </p>
                        <p>
                           <strong> Tolerability:</strong> Fewer patients withdrew because of treatment-emergent adverse events with
                            Brintellix than agomelatine (5.5% vs. 8.3%). Adverse events (incidence ≥5% in either group)
                            were nausea, headache, dizziness and somnolence. Nausea was the only treatment-emergent
                            adverse event with a higher incidence in the Brintellix group (16.2%) than in the
                            agomelatine group (9.1%).
                        </p>
                    </div>
                    <div class="licensed licensed2 pt-1">
                        <span>The licensed starting dose of Brintellix for patients aged 65 or over is 5 mg/day.
                        </span>
                        <span>APTS, all patients treated set; CGI-I, Clinical Global Impression - Improvement; CGI-S,
                            Clinical Global Impression - Severity; DFFS, Depression and Family Functioning Scale; EQ-5D,
                            DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; EuroQol 5
                            Dimensions; HAM-A, Hamilton Anxiety Rating Scale; MADRS, Montgomery-Åsberg Depression Rating
                            Scale; MDE, major depressive episode; SDS, Sheehan Disability Scale; SNRI, serotonin and
                            noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; WLQ, Work
                            Limitations Questionnaire.
                        </span>
                        <p>
                            <strong>Reference:</strong> 1. Montgomery SA et al. Hum Psychopharmacol 2014;29:470–482.
                        </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1284 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!--study 2  Modal -->
    <div class="modal fade" id="study-modal9" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span class="font-size-20">Thase ME et al. 2022¹</span>
                    <h3>
                        A 48-week, phase 4 relapse-prevention study that included a 16-week open-label period, followed
                        by a 32-week randomised, double-blind treatment period, investigating multiple Brintellix doses
                        versus placebo for relapse prevention in patients achieving remission with Brintellix 10 mg
                        daily.
                    </h3>
                    <span class="font-size-16-br"><strong>Study objective:</strong> Evaluate the efficacy of Brintellix as maintenance
                        therapy across the approved dose range using a fixed dose of Brintellix during the open-label
                        period.</span>
                        <div class="rotate-sm">
                            <figure><img src="asset/image/rotate.png" alt=""></figure>
                            <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                        </div>
                    <span class="font-size-20-blue pt-1">Six-week double-blind treatment period</span>
                    <figure class="vocational">
                        <img src="asset/image/vocational-img8.png" alt="" />
                    </figure>
                    <div class="analysis-cnt">
                        <p>
                            <strong>Primary endpoint:</strong> Time from randomisation to relapse over the first 28 weeks of the 32-week
                            double-blind treatment period.
                        </p>
                        <p>
                            Secondary endpoint: Change from baseline II in total MADRS, Clinician Global
                            Impression-Severity [CGI-S] and Clinician Global Impression-Improvement (CGI-I) and time to
                            relapse were evaluated at 32 weeks.


                        </p>
                        <p>
                            <strong>Tolerability results:</strong> All doses of Brintellix were well tolerated, with the most frequently
                            reported adverse events (AEs) during the 32-week double-blind treatment period for
                            Brintellix (all doses) versus placebo being: upper respiratory tract infections,
                            nasopharyngitis, nausea, weight increase, and back pain.
                        </p>
                    </div>
                    <div class="licensed">
                        <span>The licensed starting dose of Brintellix for patients aged 65 and over is 5 mg/day.

                        </span>
                        <span>MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, Major Depressive Disorder; MDE,
                            major depressive episode.

                        </span>
                        <p>
                            <strong>Reference:</strong> 1. Thase ME et al. J Affect Disord 2022;303:123–130.
                        </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1284 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!--study 3  Modal -->
    <div class="modal fade" id="study-modal10" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span class="font-size-20">Vieta E et al. 2017¹</span>
                    <h3>
                        A pooled post hoc analysis of the effectiveness, safety and tolerability of Brintellix during
                        five long-term (52-week) open-label extension studies of people with MDD
                    </h3>
                    <span class="font-size-16-br pdt-35"><strong>Study objective:</strong> Assess whether improvements in depressive and
                        anxiety
                        symptoms continued after acute (6- to 8-week) Brintellix treatment and whether the effectiveness
                        of long-term Brintellix treatment was affected by risk factors such as symptom severity,
                        duration of the index MDE, or number of prior MDEs.</span>
                        
                        <div class="rotate-sm">
                            <figure><img src="asset/image/rotate.png" alt=""></figure>
                            <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                        </div>
                    <figure class="vocational">
                        <img src="asset/image/vocational-img9.png" alt="" />
                    </figure>
                    <div class="analysis-cnt">
                        <p>
                            Patients included had completed one of eight short-term lead-in studies. Seven of the
                            lead-in studies were of eight weeks in duration and one study (NCT00761306) was of six weeks
                            in duration. In this study, baseline I was defined as the start of active treatment in the
                            lead-in studies and baseline II was the start of active treatment in the extension studies.


                        </p>
                        <p>
                            <strong>Efficacy assessments:</strong> The long-term effectiveness of Brintellix was assessed by mean MADRS
                            total scores, HAM-A total scores, and CGI-S scores calculated at baseline I, baseline II,
                            and the end of the extension studies.

                        </p>
                        <p>
                            <strong>Tolerability:</strong> The most commonly reported adverse event during the maintenance period was
                            nausea.
                        </p>
                    </div>
                    <div class="licensed licensed2 licensed3">
                        <span>The licensed starting dose of Brintellix for patients aged 65 or over is 5 mg/day.

                        </span>
                        <span>MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; MDE,
                            major depressive episode.

                        </span>
                        <p>
                        <strong> Reference:</strong> 1. Vieta E et al. Eur Neuropsychopharmacol 2017;27:877–884. 2. Alam MY et al. Int
                            Clin Psychopharmacol. 2014;29 :36–44. 3. Baldwin DS et al. Curr Med Res Opin 2012 ;28
                            :1717–1724. 4. Filippov G and Christens P. Eur Neuropsychopharmacol. 2013 ;23 :S325. 5.
                            Florea I et al. Eur Neuropsychopharmacol. 2012. 22 :S255–S256. 6. Jacobsen PL et al. Int J
                            Neuropsychopharmacol. 2014 ;17 :97–98.
                        </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1284 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
</body>

</html>